The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jan 28, 2025
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two medications, norepinephrine and phenylephrine, to see which one is better at preventing kidney injury and other complications after major surgeries that last at least two hours under general anesthesia. Low blood pressure is common during these surgeries, and both medications are used by anesthesiologists to help raise blood pressure back to a safe level. The trial will involve about ten hospitals in North America, where each hospital will alternate using one of the medications each month.
To participate, individuals must be 18 years or older and scheduled for a major surgery with general anesthesia that lasts two or more hours. They also need to receive intravenous vasopressors (the medications for low blood pressure) during their surgery. Patients with certain conditions, such as heart surgeries or kidney procedures, may not be eligible. Participants do not need to do anything extra for this trial, as their data will be collected as part of their usual medical care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or older
- • Surgery under general anesthesia with a surgery duration of 2 hours or more
- • Received intravenous vasopressors during surgery
- Exclusion Criteria:
- • Cardiac surgery
- • Extra-corporeal membrane oxygenation
- • Organ transplantation
- • Obstetric procedures
- • Procedures on the kidney
- • Outpatient procedures
- • Already receiving NE or PE or inotropes before induction of anesthesia (at the time of anesthesia start)
- • American Society of Anesthesiologists physical status classification 5 or 6
- • Patient for whom a local protocol recommends a specific first line vasopressor
- • Most recent documented estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m\^2 or preoperative renal replacement therapy within 60 days before surgery
- • Patients who do not have a preoperative creatinine value within 60 days before surgery
- • Alive patients who do not have a postoperative creatinine value
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
San Francisco, California, United States
Patients applied
Trial Officials
Sachin Kheterpal, MD MBA
Principal Investigator
University of Michigan
Matthieu Legrand, MD PhD
Principal Investigator
University of California, San Francisco
Allison Janda, MD
Study Director
University of Michigan
Michael P Bokoch, MD PhD
Study Director
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported